Supplementary

Subgroup analysis: numerical analysis of different centers (Only in surgical patients) $\,$

Characteristics	Xi'an (n=13)	Chongqing (n=7)
RECIST		
ORR	10 (76.9%)	4 (57.1%)
Postoperative pathology results		
MPR	8 (61.5%)	2 (28.6%)
pCR	4 (30.7%)	2 (28.6%)
Extent of Surgery		
Lobectomy	7 (53.8%)	4 (57.1%)
Bilobectomy	1 (7.7%)	1 (14.3%)
Sleeve resection/bronchoplasty	4 (30.7%)	1 (14.3%)
Pneumonectomy	1 (7.7%)	1 (14.3%)
Surgical method		
VATS/da Vinci	7 (53.8%)	7 (100%)
Conversion to thoracotomy	2 (15.4%)	0
Thoracotomy	4 (30.7%)	0

ORR, overall response rate; pCR, pathological complete response;

MPR, major pathological response.

Subgroup analysis: numerical analysis of different drug treatments (Only in surgical patients)

Characteristics	Sintilimab (n=9)	Nivolumab (n=4)	Pembrolizumab (n=7)
RECIST			
ORR	3 (33.3%)	4 (100%)	7 (100%)
Postoperative pathology results			
MPR	2 (22.2%)	4(100%)	4 (57.1%)
pCR	1 (11.1%)	2 (50%)	3 (42.8%)
AE			
Hyperthyroidism	1 (11.1%)		
Rash			1 (14.3%)
Extent of surgery			
Lobectomy	5 (55.6%)	2 (50%)	4 (57.1%)
Bilobectomy	1 (11.1%)		1 (14.3%)
Sleeve resection/bronchoplasty	2 (22.2%)	2 (50%)	1 (14.3%)
Pneumonectomy	1 (11.1%)		1 (14.3%)
Surgical method			
VATS/da Vinci	6 (66.7%)	4 (100%)	4 (57.1%)
Conversion to thoracotomy	1 (11.1%)		1 (14.3%)
Thoracotomy	2 (22.2%)		2 (28.6%)

ORR, overall response rate; pCR, pathological complete response; MPR, major pathological response; AE, adverse event.

Subgroup analysis: numerical analysis of different cycles (Only in surgical patients)

Characteristics	1–2 (n=6)	3-4 (n=14)
RECIST		
ORR	3 (50%)	11 (78.6%)
Postoperative pathology results		
MPR	3 (50%)	7 (50%)
pCR	1 (16.7%)	5 (35.7%)
AE		
Hyperthyroidism		1 (7.1%)
Rash	1 (16.7%)	
Extent of surgery		
Lobectomy	3 (50%)	8 (57.1%)
Bilobectomy		2 (14.3%)
Sleeve resection/bronchoplasty	3 (50%)	2 (14.3%)
Pneumonectomy		2 (14.3%)
Surgical method		
VATS/da Vinci	5 (83.3%)	9(64.2%)
Conversion to thoracotomy		2 (14.3%)
Thoracotomy	1 (16.7%)	3 (21.4%)

 $RECIST, Response\ Evaluation\ Criteria\ In\ Solid\ Tumors;\ MPR,\ major\ pathological\ response;\ pCR,\ pathological\ complete\ response.$